Form 4: Zenas BioPharma Director James P. Boylan Granted Stock Options

Director James P. Boylan of Zenas BioPharma, Inc. received stock options for 37,000 shares at an exercise price of $17 on September 12, 2024.

Summary

• James P. Boylan, a director of Zenas BioPharma, Inc., was granted stock options to purchase 37,000 shares of common stock on September 12, 2024.
• The exercise price of the options is $17 per share.
• The options vest in equal annual installments over three years, starting on September 12, 2025, subject to continued service.
• The options expire on September 11, 2034.
• Mr. Boylan has agreed to hold any securities granted to him for his service as a director on the Issuer's board of directors for the benefit of Enavate Sciences, LP, and disclaims beneficial ownership of the options and underlying shares.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. The disclaimer of beneficial ownership by Boylan tempers the positive sentiment slightly.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service from the director.

Management Comments

• Mr. Boylan has agreed to receive and hold for the benefit of, Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors.
• Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to attract and retain qualified board members and align their interests with those of the company and its shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry.
• The vesting schedule of three years is also typical.
• Comparable companies like BioNTech or Moderna also use stock options as part of their compensation packages for directors.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director is incentivized to contribute to the company's success.

Key Dates